

The histone deacetylase inhibitor, romidepsin, as a potential treatment for idiopathic pulmonary fibrosis

Oncotarget

8, 48737-48754

DOI: [10.18632/oncotarget.17114](https://doi.org/10.18632/oncotarget.17114)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. PLoS ONE, 2018, 13, e0207915. | 2.5 | 38 |
| 2 | Novel management strategies for idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2018, 12, 831-842. | 2.5 | 9 |
| 3 | Paracrine signalling during ZEB1-mediated epithelialâ€mesenchymal transition augments local myofibroblast differentiation in lung fibrosis. Cell Death and Differentiation, 2019, 26, 943-957. | 11.2 | 104 |
| 4 | Autophagy inhibition-mediated epithelialâ€mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. Cell Death and Disease, 2019, 10, 591. | 6.3 | 107 |
| 5 | Peptides as epigenetic modulators: therapeutic implications. Clinical Epigenetics, 2019, 11, 101. | 4.1 | 22 |
| 6 | TGFÎ²-induced fibroblast activation requires persistent and targeted HDAC-mediated gene repression. Journal of Cell Science, 2019, 132, . | 2.0 | 40 |
| 7 | HDAC inhibitors promote intestinal epithelial regeneration via autocrine TGFÎ²1 signalling in inflammation. Mucosal Immunology, 2019, 12, 656-667. | 6.0 | 56 |
| 8 | Inactivation of nuclear histone deacetylases by EP300 disrupts the MiCEE complex in idiopathic pulmonary fibrosis. Nature Communications, 2019, 10, 2229. | 12.8 | 53 |
| 9 | Reactive Oxygen Species Drive Epigenetic Changes in Radiation-Induced Fibrosis. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-27. | 4.0 | 55 |
| 10 | The Role of Epigenetic Modifications in Systemic Sclerosis: A Druggable Target. Trends in Molecular Medicine, 2019, 25, 395-411. | 6.7 | 50 |
| 11 | Dually Efficacious Medicine Against Fibrosis and Cancer. Medical Sciences (Basel, Switzerland), 2019, 7, 41. | 2.9 | 5 |
| 12 | Selective inhibition of class IIa histone deacetylases alleviates renal fibrosis. FASEB Journal, 2019, 33, 8249-8262. | 0.5 | 39 |
| 13 | Targeting the Zinc-Dependent Histone Deacetylases (HDACs) for Drug Discovery. Topics in Medicinal Chemistry, 2019, , 1-27. | 0.8 | 2 |
| 14 | HDAC8 inhibition ameliorates pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L175-L186. | 2.9 | 43 |
| 15 | Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases. Journal of Medicinal Chemistry, 2020, 63, 23-39. | 6.4 | 69 |
| 16 | Myofibroblasts and Fibrosis. Circulation Research, 2020, 127, 427-447. | 4.5 | 186 |
| 17 | Senescence in Pulmonary Fibrosis: Between Aging and Exposure. Frontiers in Medicine, 2020, 7, 606462. | 2.6 | 31 |
| 18 | Epigenetic Therapies in the Precision Medicine Era. Advanced Therapeutics, 2020, 3, 1900184. | 3.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Alveolar Epithelial Type II Cells as Drivers of Lung Fibrosis in Idiopathic Pulmonary Fibrosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2269. | 4.1 | 202 |
| 20 | Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF- β 2 signalling in COVID-19 survivors. <i>Life Sciences</i> , 2021, 266, 118883. | 4.3 | 32 |
| 21 | HDAC1 and 2 regulate endothelial VCAM-1 expression and atherogenesis by suppressing methylation of the <i>GATA6</i> promoter. <i>Theranostics</i> , 2021, 11, 5605-5619. | 10.0 | 25 |
| 22 | Histone deacetylase inhibitors in medical therapeutics. , 2021, , 597-632. | | 2 |
| 23 | The MUC5B-associated variant rs35705950 resides within an enhancer subject to lineage- and disease-dependent epigenetic remodeling. <i>JCI Insight</i> , 2021, 6, . | 5.0 | 21 |
| 24 | GSK-3 Inhibition Modulates Metalloproteases in a Model of Lung Inflammation and Fibrosis. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 633054. | 3.5 | 10 |
| 25 | Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9960-9988. | 6.4 | 26 |
| 26 | Modeling Extracellular Matrix-Cell Interactions in Lung Repair and Chronic Disease. <i>Cells</i> , 2021, 10, 2145. | 4.1 | 16 |
| 27 | Interstitial lung disease in children with Rubinsteinâ€¢aybi syndrome. <i>Pediatric Pulmonology</i> , 2022, 57, 264-272. | 2.0 | 5 |
| 28 | Bidirectional epithelialâ€¢mesenchymal crosstalk provides self-sustaining profibrotic signals in pulmonary fibrosis. <i>Journal of Biological Chemistry</i> , 2021, 297, 101096. | 3.4 | 24 |
| 29 | Epigenetic regulation in fibrosis progress. <i>Pharmacological Research</i> , 2021, 173, 105910. | 7.1 | 37 |
| 30 | Aspergillus fumigatus, One Uninucleate Species with Disparate Offspring. <i>Journal of Fungi (Basel)</i> , Tj ETQq1 1 0.784314 rgBT /Overlook 3.5 14 | | |
| 31 | CBX5/G9a/H3K9me-mediated gene repression is essential to fibroblast activation during lung fibrosis. <i>JCI Insight</i> , 2019, 4, . | 5.0 | 47 |
| 32 | Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model. <i>Oncoscience</i> , 2018, 5, 99-108. | 2.2 | 15 |
| 33 | Unilateral Pulmonary Fibrosis Due to Absence of Right Pulmonary Artery. <i>Cureus</i> , 2019, 11, e5161. | 0.5 | 0 |
| 35 | Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3080-3097. | 6.4 | 10 |
| 36 | Diagnostic Value, Prognostic Value, and Immune Infiltration of LOX Family Members in Liver Cancer: Bioinformatic Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 843880. | 2.8 | 12 |
| 37 | Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option. <i>Cells</i> , 2022, 11, 1626. | 4.1 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 38 | Novel drug delivery systems and disease models for pulmonary fibrosis. Journal of Controlled Release, 2022, 348, 95-114. | 9.9 | 29 |
| 39 | Specific epigenetic regulators serve as potential therapeutic targets in idiopathic pulmonary fibrosis. Heliyon, 2022, 8, e09773. | 3.2 | 8 |
| 40 | Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis. Frontiers in Pharmacology, 0, 13, . | 3.5 | 27 |
| 41 | Avances en la investigaci3n de los mecanismos moleculares, los blancos terap4uticos y el desarrollo de f4rmacos para la fibrosis pulmonar idiop4tica. Karger Kompass Neumolog4a, 0, , 1-18. | 0.0 | 0 |
| 42 | Mechanical stress regulates the mechanotransduction and metabolism of cardiac fibroblasts in fibrotic cardiac diseases. European Journal of Cell Biology, 2023, 102, 151288. | 3.6 | 3 |
| 43 | Dysregulation of metabolic pathways in pulmonary fibrosis. , 2023, 246, 108436. | | 6 |
| 44 | Emerging opportunities to treat idiopathic pulmonary fibrosis: Design, discovery, and optimizations of small-molecule drugs targeting fibrogenic pathways. European Journal of Medicinal Chemistry, 2023, , 115762. | 5.5 | 0 |
| 45 | <i>N</i>-(-2-Aminophenyl)-benzamide Inhibitors of Class I HDAC Enzymes with Antiproliferative and Antifibrotic Activity. Journal of Medicinal Chemistry, 0, , . | 6.4 | 0 |
| 47 | Translational Studies Reveal the Divergent Effects of Simtuzumab Targeting LOXL2 in Idiopathic Pulmonary Fibrosis. , 2023, 1, 1-12. | | 0 |
| 48 | Environmental tobacco smoke exposure exaggerates bleomycin-induced collagen overexpression during pulmonary fibrogenesis. Journal of Inflammation, 2024, 21, . | 3.4 | 0 |